AD

GRANT NO:  DAMD17-94-J-4175

TITLE:  Mapping of a Breast Carcinoma Tumor Suppressor Gene to Chromosome 11p15.5

PRINCIPAL INVESTIGATOR:  Perry Gasque-Carter, Ph.D.
                          Bernard E. Weissman, Ph.D.

CONTRACTING ORGANIZATION:  University of North Carolina at Chapel Hill
                            Chapel Hill, NC 27599-4100

REPORT DATE:  26 Jul 95

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
                Fort Detrick
                Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT:  Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Mapping of a Breast Carcinoma Tumor Suppressor Gene to Chromosome 11p15.5

Perry Gasque-Carter, Ph.D.
Bernard E. Weisman, Ph.D.

University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 27599-4100

U.S. Army Medical Research and Materiel Command
Fort Detrick
Frederick, Maryland 21702-5012

Approved for public release, distribution unlimited

The identification of human tumor suppressor genes has led to new insights into the mechanisms of human cancer development. Most of the known tumor suppressor genes were isolated by determining their chromosomal location using molecular markers or cytogenetics. By this manner, several reports have mapped a tumor suppressor gene for human breast cancer to a region of chromosome 11p15.5. Our preliminary physical map of this area suggests that this region contains less than 1000 kilobases (kb). During the last year, we have gathered cosmids, P1s and yeast artificial chromosomes (YACs) from this area for the isolation of new polymorphic markers. We have also obtained matched DNA samples from over 25 normal breast and breast tumors during the past year. During the next funding period, we plan to initiate the identification of new di- tri- and tetra-nucleotide repeats from our genomic inserts in the region. We will also start loss of heterozygosity studies to further narrow the tumor suppressor region. The availability of a novel tumor suppressor gene inactivated in 25% of breast cancers would lead to new methods for treatment and early detection and may provide important clues about the process of normal mammalian tissue development.
GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to stay within the lines to meet optical scanning requirements.

Block 1. **Agency Use Only (Leave blank)**

Block 2. **Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. **Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. **Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. **Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

- C - Contract
- G - Grant
- PE - Program
- PR - Project
- TA - Task
- WU - Work Unit
- Element
- Accession No.

Block 6. **Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. **Performing Organization Name(s) and Address(es).** Self-explanatory.

Block 8. **Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. **Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

Block 10. **Sponsoring/Monitoring Agency Report Number. (If known)**

Block 11. **Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. **Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

- DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."
- DOE - See authorities.
- NTIS - Leave blank.

Block 12b. **Distribution Code.**

- DOD - Leave blank.
- DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.
- NASA - Leave blank.
- NTIS - Leave blank.

Block 13. **Abstract.** Include a brief (Maximum 200 words) factual summary of the most significant information contained in the report.

Block 14. **Subject Terms.** Keywords or phrases identifying major subjects in the report.

Block 15. **Number of Pages.** Enter the total number of pages.

Block 16. **Price Code.** Enter appropriate price code (NTIS only).

Blocks 17 - 19. **Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. **Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Signature: [Signature]
Date: [Date]
TABLE OF CONTENTS

(1) Front Cover .................................................. 1
(2) SF 298 .......................................................... 2
(3) Foreword ....................................................... 3
(4) Table of Contents ........................................... 4
(5) Introduction .................................................. 5
(6) Body ............................................................ 6
(7) Conclusions .................................................. 6
   Figure 1 ....................................................... 7
(8) References ................................................... 8-9
(5) INTRODUCTION

Breast cancer is the most frequent cause of cancer death among North American and European women. An understanding of the basic mechanisms underlying the initiation and progression is imperative to both reducing the incidence of and improving the prognosis for the disease. Like the majority of human neoplasms, mammary carcinomas arise from epithelial cells, which suggests that insights gained from the study of breast cancer may shed light on the development and progression of various other cancers as well.

Cellular transformation can result from overabundance of oncogene product and subsequent overwhelming of normal cellular control mechanisms. Two well documented mechanisms include mutation of oncogenes or amplification of normal genes. In addition, numerous studies have suggested that the loss of a gene or genes involved in growth control may convert normal cells to their neoplastic counterparts. Demonstration of loss of heterozygosity (LOH) at specific chromosomal locations in a variety of familial cancers including retinoblastoma, Wilms' tumor and Recklinghausen's neurofibromatosis have led to the identification of tumor suppressor genes for these diseases (1). Some other cancers that have been associated with LOH are neuroblastoma, colorectal cancers, and carcinomas of the kidney, lung, and breast (1, 2). The identification of these genes by positional cloning techniques supports the same strategy for mapping putative breast carcinoma genes, particularly if LOH data have already indicated a likely location to within a 6-9 megabase pair (mb) region.

Loss of heterozygosity on the short arm of chromosome 11 has been demonstrated in many cancers, including rhabdomyosarcoma, Wilms' and other embryonal tumors, as well as tumors of the brain, bladder, lung, ovary, liver, adrenals, colon, and breast (3-16). In addition, functional studies have demonstrated loss of tumorigenicity by MCF-7 breast carcinoma cells after transfer of a whole chromosome 11 (17) and LOH at 11p15.5 by human milk epithelial cells immortalized by microinjection of SV40 DNA (18). A number of studies have narrowed the region showing LOH in breast tumors to 11p15 (19, 20) or even further, to 11p15.5 (7, 21-23).

We plan to narrow the region of LOH chromosome 11p15.5 in breast cancer to a small area amenable to positional cloning approaches. This will include the development of a long-range physical map of the region, the identification of new polymorphic markers in that region and the application of these markers to over 100 matched sets of normal and breast tumor material. This will eventually lead to the isolation of candidate genes for tumor suppressor activity in breast cancer. In addition to furthering our understanding of the basic mechanisms of oncogenic processes, identification of tumor suppressor genes and elucidation of their contribution to tumor formation and progression will aid in both diagnosis and treatment of cancers. For example, the loss of a gene product presents a situation that may be particularly amenable to nonsurgical interventions, such as gene replacement and/or drug therapy. The missing substance provided by the lost tumor suppressor gene may regulate oncogene expression, so replacement or enhancement of a tumor suppressor gene product may be a particularly valuable tool in a variety of situations.
(6) BODY

We have concentrated on two areas during the last year- the completion of a genomic contig for the tumor suppressor gene region and the isolation of DNA from matched sets of breast tumor and normal breast cells. Although both objectives have proved somewhat more difficult than anticipated, we have made substantial progress towards each goal.

A. Collection of Breast Tumor Samples

We initially isolated DNA from small pieces of breast tumor material and from either normal breast epithelium or peripheral blood cells of the patient. This has proved straightforward with the resulting collection of over 25 matched sets of DNA. However, one major problem with the use of pieces of tumor especially breast samples lies in the high content of normal stromal tissue. We are also trying to obtain sufficient DNA from paraffin-embedded sections of tumors to carry out loss of heterozygosity by PCR. This requires the expertise of a pathologist to identify distinguish between normal and tumor regions in the sections. With the aid of the Pathology Department, we have extracted DNA from selected areas on ten samples. However, these have not yielded optimal samples for PCR analyses. We are currently trying different methods including an automated DNA extraction machine to improve the quality of the DNA.

B. Contig Map

After several frustrating attempts to isolate the entire region in a YAC contig, we have switched to the use of PI and PAC vectors to complete a detailed map of the region as well as serve as reagents for the isolation of new polymorphic markers. As shown in Figure 1, we have covered approximately 170 kb of the estimated 300 kb that comprises the tumor suppressor region. We are particularly encouraged by the concordance between the NotI fragments observed in the independently isolated cosmid and PI vectors. At the time of this report, we have heard that three PI vectors containing the D11S1 marker have been found. Therefore, if any of these contain the D11S724 marker, we will have completed the contig. If not, the chances that a search for PI vectors containing D11S724 will finish the task seem very high. In the worst case, we will have to isolate the ends of several of these genomic inserts to screen for the last part of the contig. We anticipate that we will complete this task during the next year.

(7) CONCLUSIONS

We have almost isolated a complete genomic contig of the breast tumor suppressor gene region in chromosome 11p15.5. With this information, as well as the availability of an ever-increasing number of breast tumor samples, we should begin to narrow down the region of the tumor suppressor gene to less than 50kb. We will also initiate the isolation of candidate genes from this region for analysis in the breast tumor samples.
REFERENCES


